Insights - Amgen’s (AMGN) melanoma treatment, talimogene laherparepvec, showed a four-month longer interim overall survival in a phase 3 trial versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Amgen (AMGN) … Continue Reading
Read NowInsights - There’s nothing worse for an acquirer than finding out that what they are buying is not what it seems. Good news for Endo Health (ENDP) … Continue Reading
Read NowInsights - In a victory for generic-drug makers, late Wednesday, U.S. Supreme Court Chief Justice John Roberts refused to block a ruling that would temporarily stop the … Continue Reading
Read NowInsights - Sarepta Therapeutics (SRPT) revealed on Tuesday that the U.S. FDA wants the company to run a phase 3 trial before submitting a New Drug Application … Continue Reading
Premium: Read NowInsights - Dendreon (DNDN) surprised early on Tuesday, as shares were up nearly 9% in early trading despite disappointing third quarter sales for its Provenge treatment for … Continue Reading
Read NowInsights - KaloBios (KBIO) rose 6% in premarket trading on favorable third quarter results. The net loss for the third quarter of 2013 was $11.3 million, or $0.47 … Continue Reading
Read NowInsights - Products targeting rare diseases are getting lots of publicity following Shire Pharmaceuticals’ (SHRP) announced acquisition of ViroPharma (VRPH), a rare-disease biopharmaceutical company, for $4.2 billion. … Continue Reading
Read Now
